Stocks making the biggest moves after hours: Tesla, Enphase Energy, Oklo, Bristol Myers Squibb and more
Check out the companies making headlines in extended trading: Tesla — Shares were marginally lower in extended trading after first-quarter results missed analysts’ estimates on the top and bottom lines. The electric vehicle company earned an adjusted 27 cents per share on revenue of $19.34 billion, while analysts polled by LSEG were looking for 39 cents per share in earnings and $21.11 billion in revenue. Enphase Energy — The energy technology company sank more than 12% after first-quarter results missed Wall Street estimates. Enphase reported adjusted earnings of 68 cents per share on revenue of $356 million, while analysts surveyed by LSEG forecast earnings of 70 cents per share and $361 million in revenue. The low end of Enphase’s second-quarter revenue outlook also fell short of analysts’ estimates. Intuitive Surgical — The biotechnology stock lost almost 6%. The company warned that its non-GAAP gross profit margin for 2025 will range from 65% to 66.5% of revenue, down from 69.1% in 2024, reflecting estimated effects from tariffs . The outlook overshadowed beats on the top and bottom lines for the first quarter. SAP — The software stock gained nearly 7% on the heels of a first-quarter earnings beat. The company earned an adjusted $1.44 per share, while analysts polled by LSEG were looking for $1.32 per share. Oklo — The nuclear technology company pulled back nearly 11% following news that OpenAI CEO and Oklo chair Sam Altman is stepping down from the startup . The move is widely expected to give Oklo increased flexibility to pursue partnerships with hyperscalers, including OpenAI. Packaging Corporation of America — The manufacturing stock slipped more than 5% after the company’s second-quarter earnings outlook missed analysts’ estimates. PKG forecasts earnings of $2.41 per share for the current quarter, while analysts polled by FactSet were looking for $2.63 per share. Bristol Myers Squibb — The biopharmaceutical giant tumbled nearly 6%. The company said a Phase 3 trial of its drug Cobenfy failed to show a statistically significant result when used as a supplemental treatment for adults with schizophrenia. Manhattan Associates — The supply chain software provider rallied 6% after first-quarter earnings of $1.19 per share topped consensus Street estimates of $1.03 per share, according to FactSet. Non-GAAP operating margin and software license, maintenance and services revenue all exceeded what analysts were expecting, per StreetAccount. — CNBC’s Darla Mercado and Scott Schnipper contributed reporting. Get Your Ticket to Pro LIVE Join us at the New York Stock Exchange! Uncertain markets? Gain an edge with CNBC Pro LIVE , an exclusive, inaugural event at the historic New York Stock Exchange. In today’s dynamic financial landscape, access to expert insights is paramount. As a CNBC Pro subscriber, we invite you to join us for our first exclusive, in-person CNBC Pro LIVE event at the iconic NYSE on Thursday, June 12. Join interactive Pro clinics led by our Pros Carter Worth, Dan Niles and Dan Ives, with a special edition of Pro Talks with Tom Lee. You’ll also get the opportunity to network with CNBC experts, talent and other Pro subscribers during an exciting cocktail hour on the legendary trading floor. Tickets are limited!
